Robust evidence shows households are at significant risk for large adverse changes in liquid assets.
New analysis of study results suggests highest dose of aducanumab may help slow cognitive decline.
Investigators addressed the association between long-term use of hydroxychloroquine therapy and the risk for Alzheimer disease.
Stepwise screening starts with a single question on subjective memory loss.
A phase 3 trial evaluating pimavanserin (Acadia) for the treatment of dementia-related psychosis has been stopped early due to positive findings in a planned interim efficacy analysis.
Use of hearing aids is associated with lower risks for being diagnosed with Alzheimer disease, dementia, depression, anxiety, and injurious falls among elderly adults diagnosed with hearing loss.
Patients with Alzheimer disease who participated in elastic resistance exercises showed changes in depressive symptoms, muscle function, and muscle mass.
Use of acetylcholinesterase inhibitors to manage dementia-related behavioral and psychological symptoms in people with Alzheimer disease may reduce the need for psychotropic medications.
Results from a study evaluating the safety and efficacy of suvorexant (Merck) for the treatment of insomnia in patients with mild to moderate Alzheimer disease dementia were presented at the AAN meeting.
Avanir announced data from the phase 3 clinical program that evaluated AVP-786 (deudextromethorphan hydrobromide/quinidine sulfate) for the treatment of moderate-to-severe agitation in patients with Alzheimer dementia.